The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The impact of amyloid deposits in AL amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, comments on the impact of amyloid deposits in light chain (AL) amyloidosis, suggesting that light chains play a central role in disease toxicity. Dr Milani anticipates the results of clinical trials investigating whether the removal of amyloid during chemotherapy improves patient outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Pfizer, Jannsen-Cilag
Membership on Board of Directors or advisory committee: Jannsen-Cilag, Siemens
